Simultaneous aerosol and intramuscular immunization with influenza vaccine induces powerful protective local T cell and systemic antibody immune responses in pigs by Martini, Veronica et al.
of January 6, 2021.
This information is current as Pigs
Systemic Antibody Immune Responses in 
Induces Powerful Protective Local T Cell and
Immunization with Influenza Vaccine 
Simultaneous Aerosol and Intramuscular
Townsend and Elma Tchilian
Sewell, Peter Beverley, Ronan MacLoughlin, Alain 
Beckie Clark, Alejandro Nunez, Garry Dolton, Andrew
McNee, Matthew Edmans, Emmanuel Atangana Maze, 
Veronica Martini, Basu Paudyal, Tiphany Chrun, Adam
ol.2001086
http://www.jimmunol.org/content/early/2020/12/15/jimmun
 published online 16 December 2020J Immunol 
        average*
   
 4 weeks from acceptance to publicationFast Publication! •  
   
 Every submission reviewed by practicing scientistsNo Triage! •  
   
 from submission to initial decisionRapid Reviews! 30 days* •  
   
Submit online. ?The JIWhy 
Subscription
http://jimmunol.org/subscription
 is online at: The Journal of ImmunologyInformation about subscribing to 
Permissions
http://www.aai.org/About/Publications/JI/copyright.html
Submit copyright permission requests at: 
Author Choice
 Author Choice option
The Journal of ImmunologyFreely available online through 
Email Alerts
http://jimmunol.org/alerts
Receive free email-alerts when new articles cite this article. Sign up at: 
Print ISSN: 0022-1767 Online ISSN: 1550-6606. 
Copyright © 2020 The Authors All rights reserved.
1451 Rockville Pike, Suite 650, Rockville, MD 20852
The American Association of Immunologists, Inc.,
 is published twice each month byThe Journal of Immunology






















The Journal of Immunology
Simultaneous Aerosol and Intramuscular Immunization with
Influenza Vaccine Induces Powerful Protective Local T Cell
and Systemic Antibody Immune Responses in Pigs
Veronica Martini,*,† Basu Paudyal,* Tiphany Chrun,* Adam McNee,* Matthew Edmans,*
Emmanuel Atangana Maze,* Beckie Clark,* Alejandro Nunez,‡ Garry Dolton,x
Andrew Sewell,x Peter Beverley,{ Ronan MacLoughlin,! Alain Townsend,† and
Elma Tchilian*
Avaccine providing both powerful Ab and cross-reactive T cell immune responses against influenza viruses would be beneficial for
both humans and pigs. In this study, we evaluated i.m., aerosol (Aer), and simultaneous systemic and respiratory immunization
(SIM) by both routes in Babraham pigs, using the single cycle candidate influenza vaccine S-FLU. After prime and boost
immunization, pigs were challenged with H1N1pdm09 virus. i.m.-immunized pigs generated a high titer of neutralizing Abs
but poor T cell responses, whereas Aer induced powerful respiratory tract T cell responses but a low titer of Abs. SIM pigs
combined high Ab titers and strong local T cell responses. SIM showed the most complete suppression of virus shedding and the
greatest improvement in pathology. We conclude that SIM regimes for immunization against respiratory pathogens warrant
further study. The Journal of Immunology, 2021, 206: 000–000.
I mmunization against infectious diseases has been practicedfor several centuries, but identifying the best method of ad-ministering a vaccine is still often a matter of empirical experimentation. Three major considerations should make rationalimmunization easier. The first is the importance of pathogen-associated molecular patterns, which are essential for triggering
an immune response. The second is that the site of immunization
programs lymphocytes to return to it. The third is that local immune
responses are critical for protection against mucosal infection and
that many lymphocytes reside in nonlymphoid tissues and provide
tissue-resident memory. Immunization at the site of infection offers
the advantage that an immune response is generated at the site of
entry of the pathogen and should provide immediate protection.
Immunization of the respiratory tract has been demonstrated to
be highly effective against influenza, and cold-adapted, live at-
tenuated influenza vaccine (LAIV) has efficacy rates of 75–80% in
children and additionally gives some cross-reactive protec-
tion against antigenically distinct strains. However, LAIV is not
so effective in adults or the elderly. In contrast, the traditional
i.m.-inactivated seasonal human influenza vaccine provides
10–60% efficacy and induces strain-specific immunity by gener-
ation of subtype specific Abs so that repeated annual vaccination
to match new influenza variants is required (1–3). Therefore, there
is an urgent need for new immunization strategies for influenza
that provide broad and long-lasting protection.
One such strategy, which has been explored against tuberculosis
(Tb), is to combine the advantages of local and systemic immu-
nization. Parenteral Bacillus Calmette–Guérin (BCG) priming
followed by intranasal boosting with an adenovirus-vectored
vaccine expressing Ag 85A (Ad85A) markedly enhanced protec-
tion in mice (4). We have shown that simultaneous systemic and
respiratory immunization (SIM) with BCG in mice or BCG/BCG
and BCG/Ad85A in cattle enhanced protection against Tb chal-
lenge (5, 6). Uddback et al. (7, 8) have used this strategy with an
adeno vector expressing influenza nucleoprotein (NP) and shown
greatly improved and durable protection against heterosubtypic
influenza challenge in mice. These data prompted us to test SIM in
the pig model using the candidate broadly protective signal minus
influenza vaccine S-FLU. S-FLU is a pseudotyped influenza virus,
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lacking the hemagglutinin (HA) signal sequence and therefore limited
to a single cycle of replication. S-FLU induces a strong cross-reactive
T cell response but a minimal humoral response to HA when ad-
ministered mucosally (9, 10). We have shown that aerosol (Aer)
delivery of S-FLU reduces lung viral load when partially matched to
the challenge virus, correlating with a local lung T cell immune re-
sponse (11). When S-FLU was completely mismatched to the chal-
lenge virus, pathology but not viral load was reduced. This suggests
that in the absence of an Ab response, lung T cell immunity can
reduce disease severity (12). By contrast, the same S-FLU preparation
induced sterile immunity to the matched challenge virus and reduced
replication and Aer transmission to naive recipients following mis-
matched viral challenge in ferrets (12). The pig is a more relevant
large animal model because it is a natural host for influenza viruses
and has very similar respiratory anatomy to humans (13, 14). Pigs
and humans are infected by the same subtypes of influenza A
viruses and are integrally connected in the ecology of influenza.
In this study, we evaluated the efficacy of SIMwith S-FLU against
H1N1pdm09 challenge using inbred Babraham pigs, allowing a
more refined analysis of the specificity of the immune responses
using MHC class I tetramers to previously defined immunodominant
NP epitopes (15).
Materials and Methods
Vaccine and virus challenge
The H1N1 signal minus influenza vaccine (S-FLU) [eGFP*/N1(A/Eng/
195/2009)] H1(A/Eng/195/2009) containing the internal genes of
A/Puerto Rico/8/1934 virus was produced as previously described (9). The
swine isolate H1N1 A/swine/England/1353/2009 (H1N1pdm09) was used
to infect the pigs.
Animal immunization and challenge study
The animal experiment was approved by the ethical review process at Animal
and Plant Health Agency and followed the U.K. Government Animal (Sci-
entific Procedures) Act 1986. Twenty-four 5–6-wk-old Babraham large,
white, inbred female and male pigs were randomized into four groups of six
animals as follows: 1) the first group received S-FLU by Aer as previously
described (12); 2) the second group was immunized i.m. with S-FLU (i.m.);
3) the third group was immunized simultaneously i.m. and by Aer with
S-FLU (SIM), and 4) the fourth group was an unimmunized control group.
Two pigs reached their humane end points because of a pre-existing heart
condition, limiting the number of pigs in the control and i.m. groups to five
animals. During immunization, all the animals were sedated with a mixture
of 4.4 mg/kg Zoletil (zolazepam) (Virbac) and 0.044 mg/kg Domitor
(medetomidine) (Orion Pharma). Aer immunization was performed using a
small droplet size, vibrating mesh nebulizer (Aerogen Solo; Aerogen) at-
tached to a custom-made veterinary mask (12). For Aer immunization, 2 ml
of S-FLU containing 7 3 107 50% tissue culture infective dose (TCID50)
S-FLU was administered over 6–10 min. For i.m. administration, the vaccine
stock was diluted to a final volume of 4 ml containing 7 3 107 TCID50, and
2 ml was administered to each trapezius muscle behind the ear. Pigs in the
SIM group received 2 ml of 3.5 3 107 TCID50 S-FLU by Aer (as described
above) and 3.5 3 107 TCID50 S-FLU delivered in 4 ml i.m. (2 3 2 ml in
each trapezius muscle). The animals were boosted 3 wk later in a similar
manner. Three weeks after the boost, all groups were challenged with 2.8 3
106 PFU of H1N1pdm09 intranasally using a mucosal atomization device
(MAD300; Wolfe Tory Medical). For logistic reasons, the challenge was
performed in two different days so that half of the animal in each group were
challenged on 23 d postboost (DPB) and the remaining half on 25 DPB.
Animals were humanely culled at 4 d postchallenge (DPC) with an overdose
of pentobarbital sodium anesthetic. At the second cull, 1 mg/kg of anti-CD3
purified mAb (PPT3 clone, produced in-house) was infused i.v. to the pigs
10 min prior to sacrifice. Because no difference was found in analyses of the
samples challenged on different days, the results are presented together.
Gross and histopathological analyses were performed as previously de-
scribed (11, 12, 16). Briefly, the lungs were removed, and digital photo-
graphs were taken of the dorsal and ventral aspects. Macroscopic pathology
was scored blind as previously reported (17). The percentage of the lung
displaying gross lesions for each animal was calculated using image analysis
software (Fiji ImageJ) on the digital photographs. Lung tissue samples from
cranial, middle, and caudal lung lobes were taken from the right lung and
collected into 10% neutral-buffered formalin for routine histological pro-
cessing. Formalin-fixed tissues were paraffin wax embedded, and 4-mm
sections were cut and routinely stained with H&E. Immunohistochemical
detection of influenza A virus NP was performed in 4-mm tissue sections as
previously described (18). Histopathological changes in the stained lung
tissue sections were scored by a veterinary pathologist blinded to the treat-
ment group. Lung histopathology was scored using five parameters (necrosis
of the bronchiolar epithelium, airway inflammation, perivascular/bronchiolar
cuffing, alveolar exudates, and septal inflammation) on a five-point scale of
0–4 and then summed to give a total slide score ranging from 0–20 per lobe
(!1.5 3 1.5 cm2) and a total animal score from 0 to 60 (11). A mean score
for the three lung lobes was calculated for each animal. The individual lung
lobes were also scored using the “Iowa” method, which takes into account
the amount of viral Ag present in the sample, as described (19).
Tissue sample processing
Blood, spleen, bronchoalveolar lavage (BAL), and lung lobes were pro-
cessed as described previously (11, 12). Trachea and nasal turbinate mu-
cosae were separated from cartilage with tweezers and digested for 2 h at
37˚C in RPMI 1640 supplemented with 100 U/ml penicillin, 100 mg/ml
streptomycin, 2 mM L-glutamine (all from Life Technologies), 2 mg/ml
collagenase D (Roche), 1 mg/ml dispase, and 1 mg/ml of DNase (both
from Sigma-Aldrich). Tissues filaments were then mashed with the plunger
of a syringe. Isolated cells were then passed through a 70-mm cell strainer
and RBC lysed before cryopreservation in FCS and 10% DMSO. Nasal
swabs (one per nostril) were taken daily following infection with
H1N1pdm09. Viral titer in nasal swabs and BAL was determined by
plaque assay on MDCK cells as previously described (11).
Serological assays
ELISAwas performed using recombinant HA (from A/England/195/2009)
containing a C-terminal thrombin cleavage site, a trimerization sequence, a
hexahistidine tag, and a BirA recognition sequence as previously described
(20). Microneutralization (MN) was performed using standard procedures
as described previously (9, 16).
Enzyme-linked lectin assay
Enzyme-linked lectin assay (ELLA) was used to quantify neutralization of
neuraminidase (NA) enzymatic activity by Ab as described before (21).
Briefly, NUNC Immuno 96-microwell plates (Sigma-Aldrich) were coated
overnight at 4˚C with 25 mg/ml fetuin (Sigma-Aldrich) in PBS containing
0.02% sodium azide. Heat-inactivated sera and BAL were serially diluted
in DMEM supplemented with 0.1% BSA, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 2 mM L-glutamine starting at 1:40 and 1:4, respectively.
H7N1 S-FLU [eGFP/N1(A/Eng/09)] H7(Netherlands/219/2003) was used
to minimize any potential steric effect of Abs binding to H1 HA. An op-
timal concentration of H7N1 S-FLU was added to the diluted Abs for
20 min on a plate shaker. One hundred microliters of the mixture of virus and
diluted samples were then transferred to the washed coated plate and in-
cubated for 18 h at 37˚C. Peanut agglutinin–conjugated with HRP (Sigma-
Aldrich) was added at 1 mg/ml in PBS and incubated at room temperature
for 2 h. The plates were washed and developed with 50 ml of TMB (Bio-
Legend); after 5 min, the reaction was stopped with 50 ml of 1 M sulfuric
acid and absorbance measured at 450 and 630 nm. The 50% inhibition titer
was calculated as the highest dilution above the IC50 line (midpoint between
the signal generated by virus-only and medium-only wells).
B cell ELISpot assay
Cryopreserved lymphocytes from blood, spleen, and tracheobronchial
lymph nodes (TBLN) were used. Then, 107 cells/well were stimulated in
each well of a 12-well plate with the TLR7 agonist R484 at 1 mg/ml in
RPMI 1640 supplemented with 100 U/ml penicillin, 100 mg/ml strepto-
mycin, 10% FBS, and 0.1% 2-Mercaptoethanol (all from Life Technolo-
gies). After 48 h, cells were washed twice with medium and counted. Then,
5 3 105 cells were distributed in duplicate in assay plates for the detection
of HA-specific Ab-secreting cells (ASC) and in negative control wells,
whereas 0.53 105 cells per well were plated to detect all Ig-secreting cells
(positive controls). Assay plates were MultiScreen-HA ELISpot plates
(Millipore), coated with anti-porcine IgG, clone MT421 (Mabtech), or
anti-porcine IgA, A100–102A (Bethyl Laboratories) 1/500 in carbonate
buffer overnight at 4˚C. After overnight incubation at 37˚C, the plates were
washed five times with PBS containing 0.05% Tween 20 and incubated
with biotinylated HA for detection of HA-specific B cells (obtained as de-
scribed before), biotinylated keyhole limpet hemocyanin (Sigma-Aldrich) as
a negative control, both at 0.1 mg/ml in PBS, biotinylated anti-porcine IgG
(MT424; Mabtech), or anti-porcine IgA (A100-102-B; Bethyl Laboratories)
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at 1/1000 in PBS to detect all Ig-secreting cells. After a 2-h incubation, plates
were washed, and streptavidin alkaline phosphatase (Invitrogen) was added
for another hour. The plates were then developed and read. Spots detected
with keyhole limpet hemocyanin were subtracted from the HA response, and
data were presented as ASC per million cells.
Flow cytometry
Cryopreserved lymphocytes from BAL were thawed and stimulated with
H1N1pdm09 (multiplicity of infection 1) or medium as a control for 18 h at
37˚C prior to GolgiPlug (BD Biosciences) addition as per manufacturer
instructions. Following a 5-h incubation with GolgiPlug at 37˚C, cells were
stained with surface markers (Table I) before fixation and permeabilization
using Cytofix Cytoperm (BD Biosciences). Intracellular staining was then
performed, and the samples were analyzed using an LSRFortessa (BD
Biosciences). Data were analyzed by Boolean gating using FlowJo v10 (Tree
Star). For identification of tissue-resident memory T cells (TRM), three
animals from each vaccinated group and two control animals were infused
i.v. with 1 mg/kg of purified CD3 mAb (clone PPT3) and sacrificed 10 min
later, as described above. Cryopreserved lymphocytes isolated from the
different tissues were labeled with anti-mouse IgG1-allophycocyanin, which
labels the circulating intravascular cells, for 20 min at 4˚C. After two washes
with PBS, normal mouse serum was added to block any remaining binding
sites of the secondary Ab. The lymphocytes were then stained with surface
markers (Table I), including anti-porcine CD3-FITC (clone PPT3; Bio-Rad
Laboratories). As not all CD3 sites would be saturated by i.v. anti-CD3 mAb,
circulating T cells are double labeled, whereas tissue-resident T cells are
positive only for the ex vivo anti–CD3-FITC.
NP tetramer staining was performed on cryopreserved lymphocytes from
PBMC, lung, BAL, trachea, and nasal turbinate as previously described (15).
Briefly, biotinylated NP peptide-loaded swine leukocyte Ag monomers were
freshly assembled into tetramer with streptavidin Brilliant Violet (BV) 421 or
BV650 (both from BioLegend). Two million mononuclear cells were incu-
bated with protease kinase inhibitor in PBS for 30 min at 37˚C, and tetramers
were added to the cells on ice for another 30 min. Surface staining with
optimal Abs concentration in FACS buffer (PBS supplemented with 2% FCS
and 0.05% sodium azide) was performed on ice for 20 min (Table I).
Samples were washed twice with FACS buffer and fixed in 1% parafor-
maldehyde before analysis using an LSRFortessa (BD Biosciences).
Statistical analysis
GraphPad version 8.4.1 was used for statistical analysis. Kruskal–Wallis test
was used for the comparison between groups of viral load, pathology, Ab,
and T cells responses. Two-way ANOVA was used for the comparison of
neutralizing Ab and to analyze the hierarchy of the response in the dif-
ferent tissues within the same group.
Results
Virus load and lung pathology
To evaluate the efficacy of simultaneous pulmonary and systemic im-
munization, groups of six inbred Babraham pigs were immunized with
S-FLU expressing NA and coated in the HA from H1N1pmd09 i.m. or
by Aer alone or simultaneously by Aer and i.m. (SIM). The SIM group
received the same total dose as the i.m. or Aer groups but split between
the two sites. Untreated pigs were used as controls. The animals were
boosted 3 wk later and, after a further 3 wk, challenged with
H1N1pdm09 virus and culled 4 d after the challenge (Fig. 1A). Two pigs
were culled before the end of the experiment because of underlying
heart conditions, unrelated to the study, leaving five animals in the i.m.
and control groups. Virus load was assessed in nasal swabs and BAL.
The SIM pigs showed the greatest reduction of virus shedding in the
nasal swabs at all time points except for the third DPC (Fig. 1B). In the
i.m. group, two individuals shed virus consistently after challenge, but a
significant reduction in viral load was achieved on 1 DPC. Aer im-
munization did not decrease virus shedding, although two pigs did not
shed at 4 DPC (Fig. 1B). Overall i.m. and SIM significantly reduced
the viral load in the nasal swabs over time, with an average area under
the viral load/time curve of 3.46 and 2.23, respectively, compared with
9.53 and 11.46 of the Aer and control group (Fig. 1C). No virus was
detected in BAL at 4 DPC in any of the immunized groups (Fig. 1D).
The unimmunized animals showed typical gross pathology changes
in the lungs with multifocal areas of consolidation in the cranial and
medial lobes (Fig. 2A). A significant reduction in the extension and
severity of the gross changes was observed in the i.m. and SIM
groups (p = 0.02 and p = 0.005, respectively, compared with con-
trols), with a trend toward improved pathology in the Aer group that
did not reach statistical significance (Fig. 2B). A characteristic bron-
chointerstitial pneumonia, with bronchiolitis, alveolar exudation and
lymphohistiocytic infiltration in the alveolar septa and peribronchial
and perivascular areas was present in the unimmunized animals. A
reduction in the severity of these changes was observed in the im-
munized groups (Fig. 2A). Labeling of influenza A NP by immuno-
histochemistry (NP-IHC) was seen in only one animal in the i.m. and
two animals in the SIM groups (p = 0.02 and p = 0.03, respectively),
whereas most nonimmunized pigs displayed abundant labeling. NP-
IHC was reduced in the Aer group, although this was NS (p = 0.55).
Despite a reduction in gross lesions score and number of virus-infected
cells, no significant difference was found when histopathology and NP-
IHC were combined in all immunized groups (Iowa score) (Fig. 2B).
These results indicate that i.m. and SIM immunization signifi-
cantly reduced nasal virus shedding and pathology, with SIM being
more effective in virus clearance and gross lung pathology reduction.
Aer immunization did not significantly reduce nasal virus load or
pathology. All immunization regimes eliminated virus in the BAL.
Ab and B cell responses
The serum-neutralizing titer against H1N1pdm09 in the i.m. and
SIM groups increased after the boost to a peak of 4096 (50%
inhibition titer) and 1812, respectively, at 14 DPB and declined by
22 DPB after the challenge (Fig. 3A). The Aer group had a much
lower peak serum-neutralizing titer of 54 at 14 DPB (Fig. 3A). NA
inhibition activity was assessed by ELLA at 4 DPC in the serum.
i.m.-immunized animals showed the highest inhibition titer (1408)
followed by SIM (453) and Aer (14.2) (Fig. 3A).
The neutralizing titer in the BAL was highest in the Aer group
(13.4), and neutralizing activity was detectable in three of six SIM
pigs (Fig. 3B). There was no detectable neutralization in the BAL
of i.m.-immunized animals, although HA-specific Abs were pre-
sent. High levels of anti-HA IgG were present in both i.m. and
SIM groups (119.2 and 167, respectively), whereas the highest
titers of IgA were detected in the Aer and SIM groups (18.3 and
46.6, respectively) (Fig. 3B). Only very low levels of NA inhibition
were found in BAL compared with serum (Fig. 3B). We also eval-
uated the number of memory IgG and IgA HA-specific B cells in
spleen, TBLN, and blood. Very few ASC were found in the blood
before challenge or in spleen at 4 DPC (Fig. 3C). HA-specific, IgG-
secreting ASC were detected in TBLN in the Aer (48 ASC/106) and
in the SIM (25 ASC/106) groups. A lower number of HA-specific IgA
ASC were present in these groups. Only two of five i.m.-immunized
pigs had HA-specific IgG and IgA ASC in TBLN (Fig. 3C).
In summary, i.m. immunization with S-FLU induced high neu-
tralizing Ab titers in serum but a limited response in BAL, although
HA-specific Abs were present. Aer delivery generated the highest
neutralizing titers in BAL but a very low serum response. The SIM
group showed a high serum-neutralizing titer, although only half the
magnitude of i.m. alone, whereas the BAL response was lower than
in Aer only but still greater than i.m. Statistically significant numbers
of HA-specific memory B cells were detected only in the Aer group
in the local lung lymph nodes.
Cytokine production by CD4 and CD8 cells in BAL
We analyzed cytokine production of BAL T cells by intracellular
staining following ex vivo stimulation with H1N1pdm09. No T cell
response was detected in the BAL of the i.m. group. In contrast, Aer
and SIM immunization induced a strong T cell response. CD8 T cells in
the Aer and SIM groups secreted mainly IFN-g, followed by TNF, and
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the response in both groups was dominated by single IFN-g producers
(51%) followed by double secreting IFN-g–TNF (36.2%) and a smaller
proportion of triple secreting IFN-g–TNF–IL-2 cells (6.5%) (Fig. 4A).
The only significant CD4 responses were IFN-g in Aer and SIM
groups, and there were few double or triple cytokine-producing cells
(Fig. 4B). Overall, Aer produced the strongest T cell response, domi-
nated by IFN-g–producing cells. SIM induced similar T cells functions,
although the response was slightly lower in magnitude. i.m. delivery
did not generate virus-specific T cells in the BAL at 4 DPC.
NP-specific tetramer responses in the respiratory tract
and blood
We enumerated S-FLU–specific CD8 T cells in blood and different
parts of the respiratory tract (nasal turbinates, trachea, BAL, and
FIGURE 1. Experimental design and viral load in nasal swabs and BAL. (A) Babraham pigs were immunized with S-FLU by Aer, i.m., or simultaneously
by Aer and i.m. (SIM) and boosted 3 wk apart. Control animals were left untreated. All animals were challenged with H1N1pdm09 virus 3 wk after the
boost. Swabs were taken daily postchallenge, and all pigs were culled 4 DPC. Half of the pigs were infused intravenously with anti-porcine CD3 mAb
10 min prior to sacrifice. (B) Virus titer in nasal swabs measured by plaque assay at one, two, three, and 4 DPC. (C) Area under the curve (AUC) of viral
titer in the nasal swabs over time. (D) Viral titer in the BAL 4 DPC. The data represent the average of two separate assays; each data points indicates
an individual animal and the horizontal line the mean of the group. Data were analyzed using the Kruskal–Wallis test. Asterisks indicate a significant
difference from the control group: *p , 0.05, **p , 0.01, ***p , 0.001.
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FIGURE 2. Lung pathology. Pigs were immunized with S-FLU by Aer, i.m., or simultaneously by Aer and i.m. (SIM), whereas control pigs were
untreated. Three weeks postboost, pigs were challenged with H1N1pdm09. The animals were euthanized at 4 DPC, and lungs were scored for appearance of
gross (indicated with a white arrow) and histopathological lesions. Representative gross pathology, histopathology (H&E staining; original magnification
3100), and immunohistochemical NP staining (original magnification 3200) for each group are shown (A). Mild lymphoplasmacytic infiltration in
peribronchiolar areas and expansion of alveolar septa are present in groups Aer, i.m., and SIM (Z), whereas bronchioles (X) and alveolar spaces (Y) remain
free of cellular exudation (white spaces). There is a marked exudation of inflammatory cells in bronchioli and alveoli in the control group (loss of white air
spaces), and virus replication can be seen (brown labeling) in bronchiolar epithelial cells and inflammatory cells in bronchioli and alveoli. The gross and
histopathological scores for each individual in a group and the group means are shown (B), including the percentage of lung surface with lesions, the lesion
scores, and the histopathological scores (Iowa includes the NP staining). Pathology scores were analyzed using one-way nonparametric ANOVA with the
Kruskal–Wallis test. Asterisks denote significant differences: *p , 0.05, **p , 0.01, compared with control.
The Journal of Immunology 5











lung) using three NP epitope tetramers: NP290–298 DFEREGYSL (DFE),
NP101–109 NGKWMRELI (NGK), and NP217–225 IAYERMCNI (IAY), as
previously described (15) (Figs. 5, 6A, Table I). No responses were
detected against the previously identified NP252–260 EFEDLTFLA
epitope in all immunized animals (data not shown).
In nasal turbinates, the response to IAY was the strongest (5%
Aer, 1.4% i.m., and 3.4% SIM), followed by DFE (2.4% Aer, 0.7%
i.m., and 1.4% SIM) and NGK (2.2% Aer, 0.2% i.m., and 1.5%
SIM). The trachea showed similar specificity. The strongest re-
sponse was detected in the BAL. NGK+ CD8 T cells were the
biggest population (13.4% in Aer and 13.8% in SIM), followed by
IAY+ (12.7% Aer and 9.4% SIM), and a lower response was found
to DFE (6% Aer and 4.7% SIM). Strikingly, no tetramer staining
was found in the BAL of the i.m. group, in agreement with the
FIGURE 3. Systemic and local Ab responses. (A) Serum-neutralizing titers over time were determined by MN (in this study, shown as mean and SEM of
two independent assays). NA inhibition activity was assessed by ELLA at 4 DPC. (B) BAL fluid was taken at 4 DPC, and virus neutralization was analyzed
by MN, HA-specific IgG and IgA titers were measured by ELISA, and NA inhibition was assessed by ELLA. Each data point represents an individual
animal. Each serum and BAL sample was assayed twice, and a mean computed. (C) HA-specific memory B cells were detected by ELISpot in PBMC
(prechallenge), spleen, and TBLN 4 DPC. Each animal is represented by a symbol, and the mean is shown as a bar. Serum neutralization was analyzed with
two-way ANOVA, whereas Kruskal–Wallis test was used for the analysis of NA neutralization in sera, BAL samples, and ELISpot data. Asterisks denote
significance compared with control group (*p , 0.05, **p , 0.01, ***p , 0.001).
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FIGURE 4. Cytokine secretion in BAL. BAL was collected at 4 DPC. Cryopreserved cells were thawed and stimulated with H1N1pdm09 (multiplicity of
infection 1) and IFN-g, and IL-2 and TNF cytokine secretion measured in CD8 (A) and CD4 (B) cells by intracellular staining. Each symbol represents an
individual animal, and the mean is shown as a bar. The pie chart shows the mean proportion of single, double, and triple cytokine-secreting CD8 T cells for
IFN-g (I), TNF (T), and IL-2 (L). Representative plots show the cytokine-secreting cells within the CD8 (A) and CD4 (B) populations. Kruskal–Wallis test
was used to compare responses between groups, and asterisks indicate significant differences (*p , 0.05, **p , 0.01, ***p , 0.001).
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lack of intracellular cytokine staining (Fig. 4). In the lung, similar
but lower tetramer-specific responses were detected for Aer (5.5%
NGK, 7.5% IAY, and 3.5% DFE) and the SIM groups (7.9% NGK,
5% IAY, and 4.0% DFE) (Fig. 6A).
To evaluate the hierarchy of tetramer responses in different
tissues, we calculated the proportion of each tetramer among
total tetramer+ CD8 T cells (Fig. 6B). The proportions of IAY
was much higher in all respiratory tissues compared with blood
(p , 0.0001 for nasal turbinates compared with PBMC in the
Aer group) (Fig. 6). The NGK response in blood was greater
compared with all respiratory tissues (p , 0.0001 when nasal
turbinates were compared with blood for the Aer group). In
the i.m. group, less NGK+ cells were detected in all tissues
compared with Aer and SIM. In particular, a significantly lower
proportion of NGK+ CD8 T cells was found in i.m. PBMC com-
pared with Aer (p = 0.01), although they were still the dominant
NP specificity among CD8 T cells (57.1% of total tetramer+ CD8
T cells).
Finally, we assessed the numbers of TRM in the respiratory
tissues by i.v. infusion of anti-porcine CD3 mAb as previously
described (12) (Fig. 7). The majority of cells in the BAL were
inaccessible to the mAb (82.4% average of all 11 animals treated
with anti-CD3 mAb) and therefore tissue resident. In the nasal
turbinates and trachea, 11.6 and 38.8% (average of all 11 animals)
of single ex vivo–labeled CD3 cells (TRM) were detected, whereas
in the lung, 95% of the T cells were double positive, perhaps
reflecting known difficulties in extracting TRM and blood contam-
ination (22). Tetramer-positive cells were detected in both TRM
and blood-borne populations.
In summary, we detected strong NP tetramer-specific CD8 T cell
responses in the nasal turbinates, trachea, BAL, and lung of Aer-
and SIM-immunized animals. i.m. induced much lower number of
tetramer-specific cells in all tissues and none in BAL. There was a
different hierarchy of the response specificity in the respiratory
tract compared with the blood, indicating that sampling blood does
not represent responses in the local tissues.
Discussion
In this study, we investigated different routes of immunization to
determine the most effective in providing protection against
influenza A virus in pigs. We tested the traditional systemic
(i.m.) route used routinely in pigs and humans for influenza
immunization and respiratory mucosal immunization, as used
with the newer LAIV. We also performed SIM, previously shown
to be highly protective, able to induce long-lasting immune
response, and perhaps similar to prime and pull immunization
regimes that have been investigated recently (5, 7, 8, 23). In our
experiments, we administered S-FLU to the whole respiratory
tract, a procedure that has been shown in mice to be superior
to upper respiratory tract immunization in protecting against
heterologous challenge (24). We were able to do so safely be-
cause S-FLU does not contain a viable RNA segment encoding
HA. This obviates the two concerns that dictate restrictions of
LAIV to the upper respiratory tract. First, the low level of
replication of temperature-sensitive LAIV might cause lung
pathology and, second, when used to protect against pandemic
influenza viruses, reassortment of H5 or H7 with LAIV HA
could occur (9, 11, 12, 25).
FIGURE 5. Tetramer staining. (A) Gating strategy for tetramer staining of BAL cells. (B) Representative FACS plots showing DFE, NGK, and IAY
tetramers binding cells among the CD8 T cells in BAL in the different groups, highlighted in red (tetramer+ as percentage of CD8 b).
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FIGURE 6. NP-specific tetramer responses in respiratory tissues and blood. (A) Percentages of DFE, NGK, and IAY tetramer+ CD8 T cells in the
respiratory tract and PBMC. Each symbol represents an individual animal, and the mean is shown as a bar. (B) Proportion of each tetramer among total
tetramers+ CD8 T cells in different tissues. A dotted histogram for BAL of the i.m. group indicates the absence of response. The data represent the average
of two separate assays. Kruskal–Wallis test was used to compare responses between groups (A) and two-way ANOVA to compare the proportions of
tetramers in the different tissues of each group of animals (B). Asterisks denote significant differences (*p , 0.05, **p , 0.01).
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i.m. immunization induced a powerful neutralizing Ab response,
and the viral load and lung pathology were both greatly reduced.
However, T cell responses were weak in these animals and,
strikingly, could not be detected in BAL at 4 DPC. Nor were
neutralizing Abs present in BAL, although it should be noted that
harvesting BAL involves considerable dilution, so low titers of Abs
may be missed. These data indicate that i.m. immunization fails to
develop lung responses, as previously reported in mice with sea-
sonal human inactivated vaccine (26).
In contrast, in Aer animals, the serum-neutralizing titer was
much lower, but neutralizing activity was detected in BAL. The
viral load in nasal swabs was not reduced. There was a trend toward
reduced gross and histopathology, although this did not reach
significance. Aer animals made powerful CD8 and CD4 responses,
detectable in BAL, a site containing almost exclusively TRM (12).
Given the powerful T cell and neutralizing Ab responses in the
BAL, it is surprising that Aer animals showed minimal reduction
in nasal virus shedding and a weak effect on pathology, although
there was no virus in the BAL. Similarly, in a previous experiment,
pigs immunized by Aer with H3N2 S-FLU and challenged with
heterologous H1N1pdm09 virus exhibited reduced lung pathology
5 DPC but no reduction in virus shedding (12). These data contrast
with results in mice in which TRM have been shown both to
protect against weight loss following heterologous influenza
challenge and to reduce viral load (27–29). This suggests that
T cell immunity in mice can both protect against clinical disease
(weight loss) and reduce viral load, whereas in pigs, a powerful
T cells response is insufficient to protect the upper respiratory tract
from infection and shedding, although the lung viral load and
pathology are reduced. Parallel experiments using the same im-
munization regimes and challenge virus in pigs and ferrets confirm
that small animal models may not always predict the outcome in a
large animal natural host, such as the pig (12). Correlative studies
in humans suggest that cross-reactive T cells provide partial pro-
tection against influenza infection (30–32). Taken together, these
data suggest that in large animals, pigs, and humans, cross-reactive
Table I. List of Abs used for intracellular cytokine staining and NP tetramers enumeration
Ab Clone Isotype Fluorophore Supplier
Tetramer enumeration
Anti-porcine CD3 PPT3 Mouse IgG1 FITC Bio-Rad Laboratories
Anti-porcine CD4 74-12-4 Mouse IgG2b PerCP Cy5.5 BD Biosciences
Anti-porcine CD8b PG164A Mouse IgG1 PE Bio-Rad Laboratories
Anti-mouse IgG1 RMG1-1 N/A Allophycocyanin BioLegend
Intracellular cytokine staining
Anti-porcine CD3 PPT3 Mouse IgG1 FITC Bio-Rad Laboratories
Anti-porcine CD4 74-12-4 Mouse IgG2b PerCP Cy5.5 BD Biosciences
Anti-porcine CD8b PG164A Mouse IgG1 PE Bio-Rad Laboratories
Anti-porcine IFN-g P2G10 Mouse IgG1 Alexa Fluor 647 BD Biosciences
Anti-human TNF Mab11 Mouse IgG1 BV421 BioLegend
Anti-porcine IL-2 A150D3F1 Mouse IgG2a Unconjugated Invitrogen
Anti-mouse IgG2a RMG2a N/A PE Cy7 BioLegend
Anti-mouse IgG1 A85-1 N/A BV650 BD Biosciences
FIGURE 7. Porcine tissue-resident memory cells. Three pigs from the immunized groups and two control pigs were infused i.v. with CD3 mAb and
culled 10 min later. Lymphocytes were isolated and stained ex vivo with the same clone of CD3 Ab labeled with FITC as described in the Materials and
Methods. As the infused CD3 does not saturate all CD3 sites, some nasal turbinate, tracheal, and lung tissue T cells are double positive (intravascular cells).
A proportion of BAL, nasal turbinate, and tracheal cells are unstained by intravascular mAb, indicating tissue residency (top row). The top row shows
representative FACS plots for each tissue of infused animal. The bottom row shows staining in animals not infused with CD3 mAb and stained ex vivo. The
reported proportion of CD3 ex vivo+CD3 i.v.2 and CD3 ex vivo+CD3 i.v.+ are calculated from total CD3+.
10 SIM FOR INFLUENZA IN SWINE











T cell immunity can alleviate severe disease but not prevent upper
respiratory infection.
The SIM animals showed a combination of the properties of the
two immunizations. There was a good serum-neutralizing Ab re-
sponse, and neutralizing Abs were also detected in BAL, but in
contrast to i.m.-immunized animals, there was a powerful CD4 and
CD8 T cell response in the BAL, lungs, and nasal turbinates. SIM
animals showed greatly reduced viral load in nasal swabs and no
detectable virus in BAL at 4 DPC together with reduced lung
pathology. Our study shows that simultaneous systemic and Aer
immunization may have the advantage of providing both protection
against homologous challenge by induction of local and systemic
neutralizing Abs and heterologous challenge, mediated by local
and systemic T cells, including TRM. Systemic immunity may also
be of benefit because influenza virus infection can also be systemic,
and serum-neutralizing Abs may abolish viremia (33, 34). A
heterologous challenge of SIM animals would be extremely in-
teresting and confirm whether this immunization regimen is truly
advantageous.
Simultaneous and prime pull immunization regimes have had
mixed success. Although systemic prime followed by skin or re-
productive tract pull successfully generated protective TRM in
these tissues, it has been less easy to protect the respiratory tract by
the same strategy (35, 36). Our earlier experiments with BCG in
mice and cattle showed that simultaneous parenteral and intranasal
administration of BCG provided improved protection, which we
attributed to earlier local control of mycobacterial replication in
the lungs postchallenge (5, 6). However, others have not replicated
this in primates (37). Similarly, immunization with an intranasal
lentiviral Tb vaccine containing Ag 85A (pull) after BCG prime
failed to improve protection (38). In contrast, simultaneous im-
munization against influenza virus with an adenoviral vector in
mice provided improved protection for up to 8 mo compared with
s.c. or intranasal immunization alone, and TRM generated by this
immunization regimen replicated in situ (7, 8). These differing
outcomes may be partly explained by the need for additional
signals as well as the Ag. For example, an adenoviral but not ve-
sicular stomatitis virus vectored pull improved anti-Tb protection in
mice (39), and an adenoviral vector encoding NP and 4-1BB ligand
enhanced protection against influenza virus compared with NP
alone (40). In the current study, i.m. S-FLU generated very weak
T cell responses, and the data provide little evidence for recruitment
of systemic T cells to the respiratory tract following infection (pull).
However, i.m. S-FLU induce a strong neutralizing Ab response, an
essential component of influenza vaccines, but the effectiveness of
the SIM regimen might be improved by a systemic immunization
able to generate a stronger circulating memory T cell reservoir,
important for the replenishment of local responses (41).
Although local immune responses are important and, when
combined with systemic responses, may provide optimal protec-
tion, it is fundamental to know how long they persist. Lung TRM
have been shown to be short lived in mice, perhaps as a conse-
quence of the high oxygen tension of the lung microenvironment
(41, 42). However, experiments examining the persistence of
influenza-specific memory indicate that a dividing lung memory
population may persist for many months if Ag is retained in the
lung (7). Our data using Ad85Avaccine showed that lung cells from
mice immunized 23 wk previously could stimulate 85A-specific
T cells to divide, indicating long-term persistence of Ag (23).
Our data illustrate another factor that may partly explain why
some regimes have not worked. Although we have not analyzed the
entire T cell repertoire in detail, the different hierarchy of speci-
ficities of tetramer+ CD8 T cells in i.m. compared with Aer ani-
mals suggests that the route of immunization can affect the T cell
epitope specificity. Others have found that local cognate Ag rec-
ognition is fundamental for establishment of influenza-specific
TRM (43, 44) and that local immunodominance is not always
found in the circulating T cell pool, although it remains to be
shown conclusively whether these differences in immunodomi-
nance affect protection (45).
Our results in this pig influenza challenge model indicate that
SIM may offer advantages in protection against influenza viruses.
SIM induces an excellent systemic Ab response, known to correlate
with protection against homologous virus infection, as well as a
powerful local TRM response, vital for protection against heter-
ologous virus challenge. We suggest that development of SIM
strategies for other respiratory pathogens, including SARS CoV-2,
may be advantageous in providing both local protection and a high
titer of Ab. SIM strategies should also take into account the need for
local costimulatory signals and persistence of Ag in the lung.
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bovis bacillus Calmette-Guérin challenge in mice. Immunology 146: 264–270.
39. Jeyanathan, M., D. Damjanovic, C. R. Shaler, R. Lai, M. Wortzman, C. Yin,
A. Zganiacz, B. D. Lichty, and Z. Xing. 2013. Differentially imprinted innate
immunity by mucosal boost vaccination determines antituberculosis immune
protective outcomes, independent of T-cell immunity.Mucosal Immunol. 6: 612–
625.
40. Zhou, A. C., L. E. Wagar, M. E. Wortzman, and T. H. Watts. 2017. Intrinsic 4-
1BB signals are indispensable for the establishment of an influenza-specific
tissue-resident memory CD8 T-cell population in the lung. Mucosal Immunol.
10: 1294–1309.
41. Slütter, B., N. Van Braeckel-Budimir, G. Abboud, S. M. Varga, S. Salek-
Ardakani, and J. T. Harty. 2017. Dynamics of influenza-induced lung-resident
memory T cells underlie waning heterosubtypic immunity. Sci. Immunol. 2:
eaag2031.
42. Hayward, S. L., C. D. Scharer, E. K. Cartwright, S. Takamura, Z. T. Li,
J. M. Boss, and J. E. Kohlmeier. 2020. Environmental cues regulate epigenetic
reprogramming of airway-resident memory CD8+ T cells. Nat. Immunol. 21:
309–320.
43. Wakim, L. M., J. Smith, I. Caminschi, M. H. Lahoud, and J. A. Villadangos.
2015. Antibody-targeted vaccination to lung dendritic cells generates tissue-
resident memory CD8 T cells that are highly protective against influenza virus
infection. Mucosal Immunol. 8: 1060–1071.
44. McMaster, S. R., A. N. Wein, P. R. Dunbar, S. L. Hayward, E. K. Cartwright,
T. L. Denning, and J. E. Kohlmeier. 2018. Pulmonary antigen encounter reg-
ulates the establishment of tissue-resident CD8 memory T cells in the lung
airways and parenchyma. Mucosal Immunol. 11: 1071–1078.
45. Pizzolla, A., T. H. O. Nguyen, J. M. Smith, A. G. Brooks, K. Kedzieska,
W. R. Heath, P. C. Reading, and L. M. Wakim. 2017. Resident memory CD8+
T cells in the upper respiratory tract prevent pulmonary influenza virus infection.
Sci. Immunol. 2: eaam6970.
12 SIM FOR INFLUENZA IN SWINE
 by guest on January 6, 2021
http://w
w
w
.jim
m
unol.org/
D
ow
nloaded from
 
